首页> 外文期刊>Drug Design, Development and Therapy >Women taking the “blue pill” (sildenafil citrate): such a big deal?
【24h】

Women taking the “blue pill” (sildenafil citrate): such a big deal?

机译:女人服用“蓝色药丸”(枸den酸西地那非):这么大的事吗?

获取原文
       

摘要

Abstract: For years, phosphodiesterase type 5 inhibitors have been used for the treatment of erectile dysfunctions. Due to the similarities between male and female sexual response, several studies have assessed the effects of sildenafil citrate (Viagra?) in women affected by female sexual arousal disorder. The results are still conflicting and the drug is not devoid of adverse effects. Furthermore, female sexual arousal disorder is a heterogeneous condition whose underlying causes are difficult to diagnose and appropriate treatment requires a thorough sexual, psychological, and medical history along with specialist consultations. The clinician should pursue a global approach to the patient with sexual difficulties, while non-hormonal treatment such as phosphodiesterase type 5 inhibitors (ie, sildenafil citrate) should be kept as the last option.
机译:摘要:多年来,磷酸二酯酶5型抑制剂已用于治疗勃起功能障碍。由于男性和女性的性反应相似,因此有几项研究评估了枸den酸西地那非(Viagra?)对女性性唤起障碍患者的影响。结果仍然是矛盾的,该药物并非没有副作用。此外,女性性唤起障碍是一种异质性疾病,其根本原因难以诊断,而适当的治疗需要透彻的性,心理和病史以及专家咨询。临床医生应针对性障碍患者采取整体治疗方法,而非激素治疗(如磷酸二酯酶5型抑制剂(即枸sil酸西地那非))应作为最后选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号